ELYM Eliem Therapeutics
- 3.660
- -0.090-2.40%
- 3.680
- +0.020+0.55%
Eliem Therapeutics News
Stifel Nicolaus Sticks to Its Buy Rating for Eliem Therapeutics (ELYM)
Stifel Nicolaus Reaffirms Their Buy Rating on Eliem Therapeutics (ELYM)
SVB Securities Keeps Their Buy Rating on Eliem Therapeutics (ELYM)
H.C. Wainwright Sticks to Their Hold Rating for Eliem Therapeutics (ELYM)
HC Wainwright & Co. Reiterates Neutral on Eliem Therapeutics, Maintains $6 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Pacira Pharmaceuticals (PCRX) and Eliem Therapeutics (ELYM)
Eliem Therapeutics Analyst Ratings
SVB Securities Sticks to Their Buy Rating for Eliem Therapeutics (ELYM)
H.C. Wainwright Sticks to Their Buy Rating for Eliem Therapeutics (ELYM)
Eliem Therapeutics Analyst Ratings
HC Wainwright & Co. Initiates Coverage On Eliem Therapeutics With Buy Rating, Announces Price Target of $6
Eliem Therapeutics (ELYM) Has a New Rating From H.C. Wainwright
Eliem Therapeutics Price Target Cut to $4.00/Share From $9.00 by SVB Leerink
Eliem Therapeutics Analyst Ratings
SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating
SVB Securities Adjusts Eliem Therapeutics' Price Target to $9 from $13, Keeps Outperform Rating
SVB Securities Maintains a Buy Rating on Eliem Therapeutics (ELYM)
Eliem Therapeutics Price Target Cut to $9.00/Share From $13.00 by SVB Leerink
Eliem Therapeutics Is Maintained at Outperform by SVB Leerink
Eliem Therapeutics analyst ratings
Analysis
Price Target
No Data
